Alkermes PLC - (ALKS) closed at $45.37 on October 29, 2026, up 0.3% from the previous close, on volume of 1,318,479 shares (30-day average 2,258,717).
Data as of October 29, 2026.
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Business Wire (Tue, 20-Oct 4:00 PM ET)
Business Wire (Tue, 13-Oct 7:00 AM ET)
Market Chameleon (Mon, 21-Sep 3:55 AM ET)
Business Wire (Mon, 21-Sep 7:00 AM ET)
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Business Wire (Wed, 16-Sep 7:00 AM ET)
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards Program
Business Wire (Thu, 10-Sep 7:00 AM ET)
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
Business Wire (Wed, 9-Sep 8:00 AM ET)
Business Wire (Mon, 24-Aug 6:30 PM ET)
Alkermes Unveils Q1 2026 Results and Sets Full-Year Roadmap: Pipeline Expansions Take Center Stage
Market Chameleon (Tue, 5-May 5:48 AM ET)
Market Chameleon (Tue, 28-Oct 5:32 AM ET)
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Alkermes PLC - trades on the NASDAQ stock market under the symbol ALKS.
As of October 29, 2026, ALKS stock price climbed to $45.37 with 1,318,479 million shares trading.
ALKS has a beta of 0.06, meaning it tends to be less sensitive to market movements. ALKS has a correlation of 0.00 to the broad based SPY ETF.
ALKS has a market cap of $7.61 billion. This is considered a Mid Cap stock.
Last quarter Alkermes PLC - reported $496 million in Revenue and $.00 earnings per share. This beat revenue expectation by $39 million and missed earnings estimates by -$.14.
In the last 3 years, ALKS traded as high as $55.67 and as low as $22.06.
The top ETF exchange traded funds that ALKS belongs to (by Net Assets): IJR, VTI, IWM, XBI, VB.
ALKS has outperformed the market in the last year with a price return of +46.4% while the SPY ETF gained +13.1%. However, in the short term, ALKS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -10.2% vs +4.1% return in SPY. But in the last 2 weeks, ALKS shares have fared better than the market returning +16.1% compared to SPY 0.0%.
ALKS support price is $44.23 and resistance is $46.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALKS shares will trade within this expected range on the day.
